| Sources: Company Website. Company Presentation. -----
As mentioned above, SXTP has several key potential catalysts to watch for at this moment. Take a look here:
No. 1 SXTP Potential Catalyst - A Tiny Float Could Create A Volatile Situation (In Moments...).
According to info from the Yahoo Finance website, SXTP has an extremely low float.
In fact, the website reports this profile to have approx. 1.3Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
Could more positive company news in the first half of 2025 provide a near term spark? -----
No. 2 SXTP Potential Catalyst - The Signing Of A New Agreement Demonstrates Growing Confidence In The Potential Tafenoquine Is Showing.
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), ..., today announced the signing of a Patent License Agreement with Yale School of Medicine and Yale School of Public Health to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
...
“This agreement demonstrates the growing confidence 60 Degrees Pharmaceuticals, Yale School of Medicine, and Yale School of Public Health have in the potential that tafenoquine is now showing as a next-generation therapeutic for babesiosis,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Inc., Geoff Dow, PhD. “Today, a babesiosis patient who progresses past the initial stages of mild symptoms may have limited treatment options. If approved, tafenoquine has the potential to meet this growing unmet need. Tafenoquine also has the potential to become the first prophylaxis available for babesiosis.”
“Relapsing babesiosis occurs in highly immunocompromised patients, is very difficult to treat, and has an estimated mortality rate of 20 percent. There is a critical need to develop new antimicrobials for use in these patients,” said Peter James Krause, MD, Senior Research Scientist in Epidemiology (Microbial Diseases), in Medicine (Infectious Diseases) and in Pediatrics (Infectious Disease) and Lecturer in Epidemiology (Microbial Diseases) at Yale University.
Read the full article here. -----
No. 3 SXTP Potential Catalyst - Explosive Product Revenue Increase Could Signal A Bright, Growth-Oriented Future Ahead.
60 Degrees Pharmaceuticals Announces 2024 Annual Results
WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), ..., reported today their financial results for the 2024 fiscal year, ended December 31, 2024.
Financial Highlights for the Fiscal Year Ended December 31, 2024:
- Net product revenues increased 140% from $253.6k for fiscal year 2023 to $607.6k for fiscal year 2024; the Company credits growth from domestic commercial sales of ARAKODA®.
- The Company achieved a gross pro-fit of approximately $222.8k in fiscal year 2024, compared to an approximate gross loss of $221k in fiscal year 2023. Increased sales volume allowed the Company to overcome fixed cost of goods expense associated with the Drug Supply Chain Security Act that previously led to a gross loss.
...
Read the full article here. -----
No. 4 SXTP Potential Catalyst - Company Takes A "Proactive Step" To Ensure The Continuity Of Tafenoquine Supply In The U.S.
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
WASHINGTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), today announced that the United States Food and Drug Administration (FDA) does not object to the Company’s plan to import KODATEF® (tafenoquine) from Australia as a one-time, preemptive measure against any near-term disruption in the U.S. supply of ARAKODA® (tafenoquine).
ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older in the United States (U.S.) It is sold under the brand name KODATEF in Australia, where it is indicated for the prevention of malaria in adults 18 years of age and above. The two products are identical in their dosing regimens, mechanisms of action, safety and efficacy profiles, and other clinical features. KODATEF is not approved for use in the U.S.
Demand for ARAKODA has been steadily growing in recent months as awareness and use of the product has expanded across the U.S. The Company is taking the proactive step of importing KODATEF as a demonstration of its long-standing commitment to ensuring that tafenoquine for malaria prophylaxis remains readily available to healthcare providers at all times.
The Company plans to import a five-month supply of KODATEF while increasing manufacturing output of ARAKODA over the long-term.
A notice about this information is expected to be posted by FDA on its website.
Read the full article here. -----
No. 5 SXTP Potential Catalyst - Could Key Chart Support Be Growing At 4 Key Technical Levels?
Over the past week plus, SXTP has been on a heater.
Moving From a low of $1.61 on April 7th to a high of $4.41 the next day (a max run of 173%), SXTP has shown its explosive, short term potential.
It's also moved above these 4 key technical chart lines (as of close Monday):
- 5-Day Simple Moving Average (SMA)
- 20-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
If support grows at these levels, it may just be a matter of time until SXTP attempts to challenge other previous highs. -----
(Nasdaq: SXTP) Recap - Several Potential Catalysts Could Create A Breakout Spark
No. 1 - A Tiny Float Could Create A Volatile Situation (In Moments...).
No. 2 - The Signing Of A New Agreement Demonstrates Growing Confidence In The Potential Tafenoquine Is Showing.
No. 3 - Explosive Product Revenue Increase Could Signal A Bright, Growth-Oriented Future Ahead.
No. 4 - Company Takes A "Proactive Step" To Ensure The Continuity Of Tafenoquine Supply In The U.S.
No. 5 - Could Key Chart Support Be Growing At 4 Key Technical Levels? -----
Coverage is officially initiated on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP).
I'll be in touch with updates as the week moves forward. Talk again soon.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/14/2025 and ending on 04/15/2025 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid fifty two thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (SXTP:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/sxtp/#details | 
No comments:
Post a Comment